Stockscreener 앱 받기
29.01
8.04%
2.16
시간 외 거래:
29.03
0.02
+0.07%
전일 마감가:
$26.85
열려 있는:
$26.9
하루 거래량:
2.66M
Relative Volume:
2.43
시가총액:
$2.40B
수익:
$352.57M
순이익/손실:
$-143.01M
주가수익비율:
-6.4324
EPS:
-4.51
순현금흐름:
$-153.40M
1주 성능:
+3.87%
1개월 성능:
+18.46%
6개월 성능:
+25.91%
1년 성능:
+4.99%
1일 변동 폭
$26.73
$29.20
1주일 범위
$24.96
$29.53
52주 변동 폭
$20.84
$49.50
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
29.01 | 2.40B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation - Simply Wall St
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
Beam Therapeutics (BEAM) Stock Dips Amid Biotech Sector Decline - GuruFocus.com
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Beam Therapeutics CEO to Present at J.P. Morgan Healthcare Conference: Precision Gene Editing Spotlight - StockTitan
State Street Corp Purchases 437,402 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Decline in Short Interest - MarketBeat
Beam Therapeutics' SWOT analysis: base editing pioneer faces competitive gene therapy market - Investing.com
Beam Therapeutics' SWOT analysis: base editing pioneer faces competitive gene therapy market By Investing.com - Investing.com South Africa
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains - AOL
Brokers Issue Forecasts for BEAM FY2024 Earnings - MarketBeat
Beam Therapeutics announces new data from BEACON Phase 1/2 trial of BEAM-101 - MSN
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up - MSN
Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers - MSN
Beam Therapeutics (NASDAQ:BEAM) Rating Increased to Hold at Cantor Fitzgerald - MarketBeat
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
Beam Therapeutics shares hold Outperform amid clinical data By Investing.com - Investing.com Canada
Beam Therapeutics shares hold Outperform amid clinical data - Investing.com
Beam Therapeutics Advances BEAM-101 Therapy for Sickle Cell - TipRanks
ASH: Beam’s Base Editor Efficacy In Sickle Cell Disease Holds Up - News & Insights
Beam Therapeutics Achieves Breakthrough in Sickle Cell Treatment with Promising ESCAPE Platform Data - StockTitan
Beam Therapeutics Presents New Non-human Primate (NHP) Data - GlobeNewswire
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for - The Bakersfield Californian
Charles Schwab Investment Management Inc. Boosts Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 8.6%Here's Why - MarketBeat
BEAMBeam Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting - The Manila Times
Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire
Beam Therapeutics Reports Breakthrough Clinical Data for Sickle Cell Gene Therapy BEAM-101 - StockTitan
20,800 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Acquired by Polar Asset Management Partners Inc. - MarketBeat
Beam Therapeutics Inc. Appoints Sravan K. Emany as Chief Financial Officer, Effective December 19, 2024 - Marketscreener.com
Beam Therapeutics Names Sravan K. Emany as CFO - TipRanks
Beam Therapeutics names Sravan K. Emany as new CFO - Investing.com
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - The Manila Times
Beam Therapeutics Names Former Ironwood CFO & Banking Veteran Sravan Emany as New Finance Chief - StockTitan
Tom Jede - The Business Journals
Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report? - Yahoo Finance
Redmile Group LLC Has $39.47 Million Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics adds Merck executive to board By Investing.com - Investing.com Canada
Erste Asset Management GmbH Makes New $544,000 Investment in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Fmr LLC - MarketBeat
Beam Therapeutics Inc. Announces the Appointment of Chirfi Guindo to Its Board of Directors - Marketscreener.com
Beam Therapeutics adds Merck executive to board - Investing.com
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader - The Manila Times
Beam Therapeutics Expands its Board of Directors with - GlobeNewswire
Beam Therapeutics Strengthens Board with Merck's Chief Marketing Officer Chirfi Guindo - StockTitan
Beam Therapeutics Breaks Below 200-Day Moving AverageNotable for BEAM - Nasdaq
Walleye Capital LLC Raises Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
(BEAM) Trading Report - Stock Traders Daily
20,892 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Acquired by Intech Investment Management LLC - MarketBeat
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
빔 테라퓨틱스 주식 (BEAM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ciaramella Giuseppe | President |
Nov 06 '24 |
Sale |
26.36 |
51,110 |
1,347,050 |
109,150 |
| Ciaramella Giuseppe | President |
Oct 14 '24 |
Option Exercise |
2.00 |
41,754 |
83,594 |
211,370 |
| Ciaramella Giuseppe | President |
Oct 14 '24 |
Sale |
26.27 |
51,110 |
1,342,752 |
160,260 |
2.88%
2.65%
자본화:
|
볼륨(24시간):